Lucid Diagnostics Inc. 8-K

What Happened
Lucid Diagnostics, Inc. announced on April 23, 2026 that it entered into an underwriting agreement with Canaccord Genuity LLC and BTIG, LLC to sell 18,000,000 shares of its common stock in an underwritten public offering priced at $1.00 per share. Under the agreement the underwriters will purchase the shares at $0.94 per share (a $0.06 per share underwriting discount). The offering was made under the company’s shelf registration on Form S-3 (Reg. No. 333-291981) and is expected to close on or about April 24, 2026.

Key Details

• Shares offered: 18,000,000 common shares; public offering price $1.00 per share.
• Underwriter purchase price: $0.94 per share (underwriting discount $0.06).
• Gross proceeds: $18,000,000 before underwriting discount and offering expenses.
• Company obligations: reimburse certain underwriter expenses (up to $75,000), provide customary representations, indemnities and closing conditions; legal opinion from Graubard Miller attached as an exhibit.

Why It Matters
This offering provides Lucid with near-term access to capital (gross proceeds of $18.0M) which can affect the company’s cash runway and funding for operations or strategic priorities. For existing shareholders, the offering dilutes ownership because new shares are being issued. Investors should note the underwritten nature of the deal (Canaccord and BTIG acting as joint bookrunners), the agreed underwriting discount, and the expected closing date when assessing company liquidity and share supply impacts.